MA54379B1 - Nouvelles formes cristallines d'un thienopyrimidine inhibiteur de mcl-1 - Google Patents

Nouvelles formes cristallines d'un thienopyrimidine inhibiteur de mcl-1

Info

Publication number
MA54379B1
MA54379B1 MA54379A MA54379A MA54379B1 MA 54379 B1 MA54379 B1 MA 54379B1 MA 54379 A MA54379 A MA 54379A MA 54379 A MA54379 A MA 54379A MA 54379 B1 MA54379 B1 MA 54379B1
Authority
MA
Morocco
Prior art keywords
crystalline forms
thienopyrimidine
mcl
inhibitor
new crystalline
Prior art date
Application number
MA54379A
Other languages
English (en)
Other versions
MA54379A (fr
Inventor
Michael Lynch
Baets Emilie De
Julien Auvray
Nicolas Leblanc
Original Assignee
Servier Lab
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Vernalis R&D Ltd filed Critical Servier Lab
Publication of MA54379A publication Critical patent/MA54379A/fr
Publication of MA54379B1 publication Critical patent/MA54379B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des formes cristallines du composé a : (i) caractérisées par leur diagramme de diffraction de rayons x sur poudre, le spectre 13c nmr à l'état solide, le spectre mir et le spectre raman ainsi que des compositions pharmaceutiques les contenant.
MA54379A 2018-12-06 2019-12-05 Nouvelles formes cristallines d'un thienopyrimidine inhibiteur de mcl-1 MA54379B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18306634 2018-12-06
PCT/EP2019/083773 WO2020115183A1 (fr) 2018-12-06 2019-12-05 Nouvelles formes cristallines d'un inhibiteur mcl-1, procédé de préparation associé et compositions pharmaceutiques les contenant

Publications (2)

Publication Number Publication Date
MA54379A MA54379A (fr) 2021-10-13
MA54379B1 true MA54379B1 (fr) 2023-12-29

Family

ID=64665802

Family Applications (1)

Application Number Title Priority Date Filing Date
MA54379A MA54379B1 (fr) 2018-12-06 2019-12-05 Nouvelles formes cristallines d'un thienopyrimidine inhibiteur de mcl-1

Country Status (26)

Country Link
US (2) US12129261B2 (fr)
EP (1) EP3891156B1 (fr)
JP (1) JP7649241B2 (fr)
KR (1) KR102855345B1 (fr)
CN (1) CN113166169A (fr)
AR (1) AR117255A1 (fr)
AU (1) AU2019391329B2 (fr)
BR (1) BR112021010072A2 (fr)
CA (1) CA3121363A1 (fr)
DK (1) DK3891156T3 (fr)
EA (1) EA202191534A1 (fr)
ES (1) ES2971258T3 (fr)
FI (1) FI3891156T3 (fr)
HR (1) HRP20240211T1 (fr)
HU (1) HUE065266T2 (fr)
IL (1) IL283656B2 (fr)
LT (1) LT3891156T (fr)
MA (1) MA54379B1 (fr)
MD (1) MD3891156T2 (fr)
MX (1) MX2021006702A (fr)
PL (1) PL3891156T3 (fr)
PT (1) PT3891156T (fr)
RS (1) RS65047B1 (fr)
SI (1) SI3891156T1 (fr)
TW (1) TWI905090B (fr)
WO (1) WO2020115183A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7673255B2 (ja) 2021-06-11 2025-05-08 ギリアード サイエンシーズ， インコーポレイテッド Ｍｃｌ－１阻害剤と抗体薬物コンジュゲートとの組み合わせ
TWI910028B (zh) 2021-06-11 2025-12-21 美商基利科學股份有限公司 Mcl-1抑制劑與抗癌劑之組合

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3008975A1 (fr) * 2013-07-23 2015-01-30 Servier Lab Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3015483B1 (fr) * 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037957B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3046792B1 (fr) * 2016-01-19 2018-02-02 Les Laboratoires Servier Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
PT3891156T (pt) 2024-01-16
FI3891156T3 (fi) 2024-02-07
KR102855345B1 (ko) 2025-09-03
TW202039511A (zh) 2020-11-01
RS65047B1 (sr) 2024-02-29
IL283656A (en) 2021-07-29
US20250011337A1 (en) 2025-01-09
TWI905090B (zh) 2025-11-21
DK3891156T3 (da) 2024-02-19
HRP20240211T1 (hr) 2024-04-26
AR117255A1 (es) 2021-07-21
EA202191534A1 (ru) 2021-10-27
JP2022511495A (ja) 2022-01-31
AU2019391329A1 (en) 2021-07-01
MD3891156T2 (ro) 2024-06-30
CA3121363A1 (fr) 2020-06-11
AU2019391329B2 (en) 2024-09-26
LT3891156T (lt) 2023-12-27
NZ776907A (en) 2025-05-02
US12129261B2 (en) 2024-10-29
ES2971258T3 (es) 2024-06-04
MX2021006702A (es) 2021-07-07
HUE065266T2 (hu) 2024-05-28
US20220017533A1 (en) 2022-01-20
BR112021010072A2 (pt) 2021-08-24
IL283656B1 (en) 2025-06-01
SI3891156T1 (sl) 2024-03-29
PL3891156T3 (pl) 2024-05-13
EP3891156B1 (fr) 2023-11-15
EP3891156A1 (fr) 2021-10-13
IL283656B2 (en) 2025-10-01
MA54379A (fr) 2021-10-13
CN113166169A (zh) 2021-07-23
KR20210100148A (ko) 2021-08-13
JP7649241B2 (ja) 2025-03-19
WO2020115183A1 (fr) 2020-06-11

Similar Documents

Publication Publication Date Title
PH12021550310A1 (en) Novel sulfonamideurea compounds
EA200870117A1 (ru) Азаиндоловые ингибиторы аурора-киназ
EA200401607A1 (ru) Ингибиторы в отношении активации ap-1 и nfat
CR20200588A (es) Compuestos novedosos
SA521422143B1 (ar) 15-pgdh مثبط
EA200802119A1 (ru) Новая кристаллическая форма vi агомелатина, способ его получения и фармацевтические композиции, которые ее содержат
EP4474017A3 (fr) Nouveaux composés hétérocycliques
CL2004000917A1 (es) Compuestos derivados de tiazol; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de enfermedades mediadas por 3-cinasa de dosfatidilnositol tal como enfermedades respiratorias, alergias, artritis reumatoide, osteoa
NO20061793L (no) 1,4-disubstituerte isoquinilonderlvater som RAF-kinaseinhibitorer nyttige for behandling av proliferative sykdommer
MXPA05009969A (es) Metodo para aislar la forma cristalina i de la 5-azacitidina.
TW200716619A (en) Heterocyclic compound
EA200600322A1 (ru) β-КРИСТАЛЛИЧЕСКАЯ ФОРМА ГИДРОХЛОРИДА ИВАБРАДИНА, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, КОТОРЫЕ ЕЁ СОДЕРЖАТ
EA200601271A1 (ru) Новая кристаллическая форма iv агомелатина, способ её получения и фармацевтические композиции, которые её содержат
MX2021004474A (es) Compuestos que contienen deuterio.
CR20230496A (es) Compuestos heterocíclicos
TW200716163A (en) A therapeutic agent for aβ related disorders
JO2793B1 (en) New Crystaline form V of Agomelatine, A process for It's Preparation and Pharmaceutical Compositions Containig it.
MA33618B1 (fr) Agent thérapeutique destiné aux troubles de l'humeur
MA54386B1 (fr) Modulateurs de trex1
WO2013152277A3 (fr) Analogues de la moénomycine, procédés de synthèse, et leurs utilisations
MX2009004343A (es) Compuestos organicos.
PH12021550512A1 (en) Imidazopyridinone compound
TW200720399A (en) Light-emitting element and iridium complex
JOP20210157A1 (ar) تخليق 3-ميثيل-1، 2، 4-ثياديازول-5-كربوهيدرازيد أو ميثيل-d3 مُعَالَج بالديوتيريوم منه
TW200612920A (en) Novel imidazolidine derivatives